glp-1 supply shortage news november 2025 Nutritional Support Market Size & Share 2025-2035 The GLP-1 drug shortage is

As que, este primer anlogo del GLP-1 oral, adems de ser una nueva y nica opcin arGLP-1 para tratar la diabetes sin inyecciones, podra representar un nuevo estndar para el tratamiento de la diabetes tipo 2 3 , afirma Francisco Pajuelo, director mdico de Novo Nordisk Espaa

207 A recent study introduced new experiment designs using HepatoPac (Hepregen Corporation, Medford, MA, USA), spheroids or liver-on-a-chip models to assess the modulation of CYPs and transporter gene expression by peptides, but further large-scale experiments are still needed

Curr Med Res Opin 2009;25:2401-2411

About Lambda Lambda & Novum delivers full-service CRO services to the innovator, biotech, and generic pharmaceutical industries worldwide

Themes continuing from 2025 into 2026 As the obesity market moves into its acceleration phase, several trends that gained traction in 2025 will continue to influence strategies and market dynamics in 2026: As the obesity market evolves, there is a growing recognition that use of obesity medications to maintain weight will be critical for many people

For type 2 diabetes, NICE recommends GLP-1 agonists when other treatments haven't achieved target HbA1c levels, with specific consideration for cardiovascular and renal risk factors according to NICE guideline NG28